Tinlarebant not checked

Belite Bio, Inc · LBS-008 · BPN-14967

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
7 in total · 3 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Geographic Atrophy, STGD1, Stargardt Disease 1
Main trialPhase 3
“This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.”In the company’s words, NCT05949593 on ClinicalTrials.gov
Other names
LBS-008 · BPN-14967

Other drugs for Geographic Atrophy

All 23 drugs for Geographic Atrophy

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 30 Jun 2027 Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
Phase 2/3Active, not recruiting Feb 2028 A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
Phase 3Completed 4 Aug 2025 Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
Phase 1/2Completed 15 Aug 2023 This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease
Phase 1Completed 20 Dec 2019 Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults
Phase 1Completed 4 Jan 2023 Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85
Phase 3Authorised not given An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tinlarebant

Following is part of Solo: you see every change to Tinlarebant the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in